---
title: "Innoviva unit Nortiva Bio launches to develop monthly long-acting oral medicines"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290220558.md"
description: "Innoviva Inc. launched its wholly owned subsidiary, Nortiva Bio, to develop long-acting oral medicines using the LYNX drug delivery platform. This technology aims to convert daily pills into single doses lasting up to a month. The lead program is a once-monthly oral contraceptive, supported by a $5 million grant from the Gates Foundation. Innoviva acquired the LYNX platform from Lyndra Therapeutics in 2025."
datetime: "2026-06-18T15:18:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290220558.md)
  - [en](https://longbridge.com/en/news/290220558.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290220558.md)
generator: "portal-rs"
---

# Innoviva unit Nortiva Bio launches to develop monthly long-acting oral medicines

-   Innoviva launched wholly owned subsidiary Nortiva Bio as a clinical-stage developer of long-acting oral medicines using the LYNX drug delivery platform. \* LYNX aims to convert daily pills into single oral doses lasting up to a month, supporting a partnering strategy to expand its pipeline. \* Lead program targets a once-monthly oral contraceptive backed by a USD 5 million Gates Foundation grant. \* Innoviva acquired the LYNX platform from Lyndra Therapeutics in 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innoviva Inc. published the original content used to generate this news brief on June 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [INVA.US](https://longbridge.com/en/quote/INVA.US.md)

## Related News & Research

- [Innoviva (INVA) Faces A Valuation Test, Is The Discount Too Wide?](https://longbridge.com/en/news/297070623.md)
- [Connor Clark & Lunn Investment Management Ltd. Acquires Shares of 52,479 Innoviva, Inc. $INVA](https://longbridge.com/en/news/297479268.md)
- [FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients](https://longbridge.com/en/news/297236507.md)
- [Novartis' oral multiple sclerosis drug meets main goal in late stage studies](https://longbridge.com/en/news/297610598.md)
- [Neuroone Medical Technologies Corp - Announces Successful Robotic-Assisted Drug Delivery Using Stereoced Platform - SEC Filing](https://longbridge.com/en/news/297194419.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**